Crossmark Global Holdings Inc. Takes $449,000 Position in INC Research Holdings, Inc. (NASDAQ:INCR)

Crossmark Global Holdings Inc. purchased a new stake in INC Research Holdings, Inc. (NASDAQ:INCR) during the third quarter, according to its most recent filing with the SEC. The fund purchased 8,580 shares of the company’s stock, valued at approximately $449,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in INC Research by 14.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,765 shares of the company’s stock valued at $103,000 after acquiring an additional 228 shares during the last quarter. Pacad Investment Ltd. bought a new stake in shares of INC Research in the 2nd quarter worth about $123,000. Riverhead Capital Management LLC bought a new stake in shares of INC Research in the 2nd quarter worth about $128,000. Victory Capital Management Inc. increased its holdings in shares of INC Research by 17.6% in the 2nd quarter. Victory Capital Management Inc. now owns 2,377 shares of the company’s stock worth $139,000 after buying an additional 356 shares during the last quarter. Finally, Shelton Capital Management bought a new stake in shares of INC Research in the 2nd quarter worth about $247,000. Institutional investors own 99.56% of the company’s stock.

INC Research Holdings, Inc. (NASDAQ:INCR) traded up $1.35 during trading on Thursday, reaching $39.30. 842,887 shares of the company’s stock traded hands, compared to its average volume of 928,713. INC Research Holdings, Inc. has a 12 month low of $33.60 and a 12 month high of $61.10. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.27 and a current ratio of 1.27. The stock has a market cap of $3,980.76, a PE ratio of 17.50, a price-to-earnings-growth ratio of 1.20 and a beta of 1.08.

INC Research (NASDAQ:INCR) last posted its quarterly earnings results on Thursday, November 9th. The company reported $0.54 EPS for the quarter, missing the consensus estimate of $0.63 by ($0.09). INC Research had a negative net margin of 4.29% and a positive return on equity of 14.42%. The business had revenue of $592.21 million during the quarter, compared to the consensus estimate of $604.95 million. During the same quarter in the prior year, the firm posted $0.64 EPS. The company’s revenue for the quarter was up 128.2% compared to the same quarter last year. research analysts predict that INC Research Holdings, Inc. will post 2.15 earnings per share for the current year.

In related news, CFO Gregory S. Rush sold 9,703 shares of the business’s stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $54.48, for a total transaction of $528,619.44. Following the completion of the transaction, the chief financial officer now owns 78,593 shares in the company, valued at approximately $4,281,746.64. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Alistair Macdonald sold 2,348 shares of the business’s stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $54.60, for a total transaction of $128,200.80. Following the transaction, the chief executive officer now owns 99,453 shares of the company’s stock, valued at approximately $5,430,133.80. The disclosure for this sale can be found here. In the last 90 days, insiders sold 16,733 shares of company stock valued at $912,270. Company insiders own 0.24% of the company’s stock.

A number of analysts have recently weighed in on the stock. TheStreet upgraded shares of INC Research from a “c” rating to a “b-” rating in a report on Monday, November 6th. Credit Suisse Group assumed coverage on shares of INC Research in a report on Wednesday, October 11th. They issued an “outperform” rating and a $68.00 target price on the stock. Jefferies Group raised shares of INC Research from a “hold” rating to a “buy” rating and lifted their price target for the stock from $62.50 to $69.00 in a research note on Monday, October 9th. Robert W. Baird reaffirmed a “buy” rating and set a $67.00 price target on shares of INC Research in a research note on Monday, October 9th. Finally, Zacks Investment Research cut shares of INC Research from a “buy” rating to a “hold” rating in a research note on Wednesday, October 4th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $52.67.

ILLEGAL ACTIVITY WARNING: “Crossmark Global Holdings Inc. Takes $449,000 Position in INC Research Holdings, Inc. (NASDAQ:INCR)” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/12/07/8580-shares-in-inc-research-holdings-inc-incr-acquired-by-crossmark-global-holdings-inc.html.

INC Research Company Profile

INC Research Holdings, Inc is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services.

Institutional Ownership by Quarter for INC Research (NASDAQ:INCR)

Receive News & Ratings for INC Research Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INC Research Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply